Document Type

Article

Publication Date

10-9-2014

Publication Title

BioMed Central Infectious Diseases

Abstract

Aminoglycosides are a critical component of multidrug-resistant tuberculosis (MDR-TB) treatment but data on their efficacy and adverse effects in Botswana is scarce. We determined the effect of amikacin on treatment outcomes and development of hearing loss in MDR-TB patients. Patients started on MDR-TB treatment between 2006 and 2012 were included. Multivariate analysis was used to determine the effect of amikacin on treatment outcomes and development of hearing loss.

DOI

10.1186/1471-2334-14-542

Comments

Chawangwa Modongo;Rafal S Sobota;Boikobo Kesenogile;Ronald Ncube;Giorgio Sirugo;Scott M Williams;Nicola M Zetola

Share

COinS